RETA
$78.69
Reata Pharma
($7.24)
(8.43%)
RETA
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($2.58)
Revenue:  $1.40 Mil
Monday
Feb 7
6:40 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RETA reports earnings?
Beat
Meet
Miss

Where is RETA's stock price going from here?
Up
Flat
Down
Stock chart of RETA
Analysts
Summary of analysts' recommendations for RETA
Score
Grade
Pivots
Resistance
$95.25
$91.52
$85.11

$81.38

Support
$74.97
$71.24
$64.83
Tweet
Growth
Description
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States.